Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.

Liu W, Meridew JA, Aravamudhan A, Ligresti G, Tschumperlin DJ, Tan Q.

Respir Res. 2019 Dec 11;20(1):281. doi: 10.1186/s12931-019-1253-1.

2.

Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis.

Haak AJ, Kostallari E, Sicard D, Ligresti G, Choi KM, Caporarello N, Jones DL, Tan Q, Meridew J, Diaz Espinosa AM, Aravamudhan A, Maiers JL, Britt RD Jr, Roden AC, Pabelick CM, Prakash YS, Nouraie SM, Li X, Zhang Y, Kass DJ, Lagares D, Tager AM, Varelas X, Shah VH, Tschumperlin DJ.

Sci Transl Med. 2019 Oct 30;11(516). pii: eaau6296. doi: 10.1126/scitranslmed.aau6296.

PMID:
31666402
3.

TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression.

Jones DL, Haak AJ, Caporarello N, Choi KM, Ye Z, Yan H, Varelas X, Ordog T, Ligresti G, Tschumperlin DJ.

J Cell Sci. 2019 Oct 18;132(20). pii: jcs233486. doi: 10.1242/jcs.233486.

PMID:
31527052
4.

PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.

Caporarello N, Meridew JA, Jones DL, Tan Q, Haak AJ, Choi KM, Manlove LJ, Prakash YS, Tschumperlin DJ, Ligresti G.

Thorax. 2019 Aug;74(8):749-760. doi: 10.1136/thoraxjnl-2019-213064. Epub 2019 Jun 10.

5.

CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis.

Ligresti G, Caporarello N, Meridew JA, Jones DL, Tan Q, Choi KM, Haak AJ, Aravamudhan A, Roden AC, Prakash YS, Lomberk G, Urrutia RA, Tschumperlin DJ.

JCI Insight. 2019 May 16;5. pii: 127111. doi: 10.1172/jci.insight.127111.

6.

Nascent Lung Organoids Reveal Epithelium- and Bone Morphogenetic Protein-mediated Suppression of Fibroblast Activation.

Tan Q, Ma XY, Liu W, Meridew JA, Jones DL, Haak AJ, Sicard D, Ligresti G, Tschumperlin DJ.

Am J Respir Cell Mol Biol. 2019 Nov;61(5):607-619. doi: 10.1165/rcmb.2018-0390OC.

PMID:
31050552
7.

Survivin IPF: Targeting Cellular Metabolism to Promote Apoptosis in IPF Fibroblasts.

Jones DL, Ligresti G.

Am J Respir Cell Mol Biol. 2019 Jan;60(1):5-6. doi: 10.1165/rcmb.2018-0270ED. No abstract available.

8.

RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation.

Oh RS, Haak AJ, Smith KMJ, Ligresti G, Choi KM, Xie T, Wang S, Walters PR, Thompson MA, Freeman MR, Manlove LJ, Chu VM, Feghali-Bostwick C, Roden AC, Schymeinsky J, Pabelick CM, Prakash YS, Vassallo R, Tschumperlin DJ.

J Cell Sci. 2018 May 15;131(10). pii: jcs209932. doi: 10.1242/jcs.209932.

9.

The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.

Paulitti A, Andreuzzi E, Bizzotto D, Pellicani R, Tarticchio G, Marastoni S, Pastrello C, Jurisica I, Ligresti G, Bucciotti F, Doliana R, Colladel R, Braghetta P, Poletto E, Di Silvestre A, Bressan G, Colombatti A, Bonaldo P, Mongiat M.

Oncogene. 2018 Jun;37(25):3399-3414. doi: 10.1038/s41388-017-0107-x. Epub 2018 Feb 27.

PMID:
29483644
10.

Mechanosensing and fibrosis.

Tschumperlin DJ, Ligresti G, Hilscher MB, Shah VH.

J Clin Invest. 2018 Jan 2;128(1):74-84. doi: 10.1172/JCI93561. Epub 2018 Jan 2. Review.

11.

Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms.

Drinane MC, Yaqoob U, Yu H, Luo F, Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S, Shah VH.

JCI Insight. 2017 Dec 21;2(24). pii: 92821. doi: 10.1172/jci.insight.92821.

12.

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.

13.

Hyperactive FOXO1 results in lack of tip stalk identity and deficient microvascular regeneration during kidney injury.

Dang LTH, Aburatani T, Marsh GA, Johnson BG, Alimperti S, Yoon CJ, Huang A, Szak S, Nakagawa N, Gomez I, Ren S, Read SK, Sparages C, Aplin AC, Nicosia RF, Chen C, Ligresti G, Duffield JS.

Biomaterials. 2017 Oct;141:314-329. doi: 10.1016/j.biomaterials.2017.07.010. Epub 2017 Jul 7.

14.

Cellular senescence mediates fibrotic pulmonary disease.

Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, Oberg AL, Birch J, Salmonowicz H, Zhu Y, Mazula DL, Brooks RW, Fuhrmann-Stroissnigg H, Pirtskhalava T, Prakash YS, Tchkonia T, Robbins PD, Aubry MC, Passos JF, Kirkland JL, Tschumperlin DJ, Kita H, LeBrasseur NK.

Nat Commun. 2017 Feb 23;8:14532. doi: 10.1038/ncomms14532.

15.

Maintenance of vascular integrity by pericytes is essential for normal kidney function.

Lemos DR, Marsh G, Huang A, Campanholle G, Aburatani T, Dang L, Gomez I, Fisher K, Ligresti G, Peti-Peterdi J, Duffield JS.

Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1230-F1242. doi: 10.1152/ajprenal.00030.2016. Epub 2016 Jun 22.

16.

A Novel Three-Dimensional Human Peritubular Microvascular System.

Ligresti G, Nagao RJ, Xue J, Choi YJ, Xu J, Ren S, Aburatani T, Anderson SK, MacDonald JW, Bammler TK, Schwartz SM, Muczynski KA, Duffield JS, Himmelfarb J, Zheng Y.

J Am Soc Nephrol. 2016 Aug;27(8):2370-81. doi: 10.1681/ASN.2015070747. Epub 2015 Dec 11.

17.

Dicer1 activity in the stromal compartment regulates nephron differentiation and vascular patterning during mammalian kidney organogenesis.

Nakagawa N, Xin C, Roach AM, Naiman N, Shankland SJ, Ligresti G, Ren S, Szak S, Gomez IG, Duffield JS.

Kidney Int. 2015 Jun;87(6):1125-40. doi: 10.1038/ki.2014.406. Epub 2015 Feb 4.

18.

Innovations in preclinical biology: ex vivo engineering of a human kidney tissue microperfusion system.

Kelly EJ, Wang Z, Voellinger JL, Yeung CK, Shen DD, Thummel KE, Zheng Y, Ligresti G, Eaton DL, Muczynski KA, Duffield JS, Neumann T, Tourovskaia A, Fauver M, Kramer G, Asp E, Himmelfarb J.

Stem Cell Res Ther. 2013;4 Suppl 1:S17. doi: 10.1186/scrt378. Epub 2013 Dec 20. Review.

19.

Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors.

Aplin AC, Ligresti G, Fogel E, Zorzi P, Smith K, Nicosia RF.

Angiogenesis. 2014 Jan;17(1):147-61. doi: 10.1007/s10456-013-9384-3. Epub 2013 Oct 4.

PMID:
24091496
20.

Advances in targeting signal transduction pathways.

McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN.

Oncotarget. 2012 Dec;3(12):1505-21. Review.

21.

Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.

Campanholle G, Ligresti G, Gharib SA, Duffield JS.

Am J Physiol Cell Physiol. 2013 Apr 1;304(7):C591-603. doi: 10.1152/ajpcell.00414.2012. Epub 2013 Jan 16. Review.

22.

The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context-dependent inhibitory and stimulatory properties.

Ligresti G, Aplin AC, Dunn BE, Morishita A, Nicosia RF.

PLoS One. 2012;7(8):e41387. doi: 10.1371/journal.pone.0041387. Epub 2012 Aug 14.

23.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM.

Curr Pharm Des. 2012;18(13):1784-95. Review.

PMID:
22394167
24.

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).

Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, Libra M.

Int J Oncol. 2012 Mar;40(3):639-44. doi: 10.3892/ijo.2011.1312. Epub 2011 Dec 20. Review.

PMID:
22200790
25.

MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.

Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A, Mongiat M.

Oncogene. 2012 Jun 28;31(26):3136-47. doi: 10.1038/onc.2011.487. Epub 2011 Oct 24.

PMID:
22020326
26.

Paracrine regulation of angiogenesis by different cell types in the aorta ring model.

Nicosia RF, Zorzi P, Ligresti G, Morishita A, Aplin AC.

Int J Dev Biol. 2011;55(4-5):447-53. doi: 10.1387/ijdb.103222rn. Review.

27.

Macrophage-derived tumor necrosis factor-alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury.

Ligresti G, Aplin AC, Zorzi P, Morishita A, Nicosia RF.

Arterioscler Thromb Vasc Biol. 2011 May;31(5):1151-9. doi: 10.1161/ATVBAHA.111.223917. Epub 2011 Mar 3.

28.

The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.

Mongiat M, Marastoni S, Ligresti G, Lorenzon E, Schiappacassi M, Perris R, Frustaci S, Colombatti A.

Neoplasia. 2010 Apr;12(4):294-304.

29.

Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression.

Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Traval S, McCubrey JA, Canevari S, Libra M.

Cell Cycle. 2010 Feb 1;9(3):557-63.

PMID:
20081364
30.

The involvement of the transcription factor Yin Yang 1 in cancer development and progression.

Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M.

Cell Cycle. 2009 May 1;8(9):1367-72. Epub 2009 May 26. Review.

PMID:
19342874
31.

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.

Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M.

Cell Cycle. 2009 May 1;8(9):1352-8. Epub 2009 May 23. Review.

32.

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA.

Leukemia. 2009 Jan;23(1):25-42. doi: 10.1038/leu.2008.246. Epub 2008 Sep 18. Review.

33.

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.

McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Bäsecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahon M, Evangelisti C, Martelli AM.

Leukemia. 2008 Nov;22(11):2080-90. doi: 10.1038/leu.2008.207. Epub 2008 Aug 7.

PMID:
18685611
34.

Extracellular matrix: a matter of life and death.

Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M.

Connect Tissue Res. 2008;49(3):203-6. doi: 10.1080/03008200802143190. Review.

PMID:
18661343
35.

Breast cancer: Molecular basis and therapeutic strategies (Review).

Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R, Malaponte G, Cappellani A, McCubrey JA, Stivala F.

Mol Med Rep. 2008 Jul-Aug;1(4):451-8.

PMID:
21479431
36.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS.

Adv Enzyme Regul. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006. Epub 2008 Feb 21. No abstract available.

37.

EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.

Doliana R, Veljkovic V, Prljic J, Veljkovic N, De Lorenzo E, Mongiat M, Ligresti G, Marastoni S, Colombatti A.

Matrix Biol. 2008 Mar;27(2):96-106. Epub 2007 Oct 10.

PMID:
17988845
38.

Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2.

Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, Colombatti A.

Mol Cell Biol. 2007 Oct;27(20):7176-87. Epub 2007 Aug 13.

39.

Absence of BRAF gene mutation in non-melanoma skin tumors.

Libra M, Malaponte G, Bevelacqua V, Siciliano R, Castrogiovanni P, Fulvi A, Micali G, Ligresti G, Mazzarino MC, Stivala F, Travali S, McCubrey JA.

Cell Cycle. 2006 May;5(9):968-70. Epub 2006 May 1.

PMID:
16687919

Supplemental Content

Loading ...
Support Center